2616 fundamentals
CSTONE PHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss
The total revenue of 2616 for the last semiannual is 218.63 M HKD, and it's 26.07% lower compared to the previous semiannual. The net income of H2 23 is -170.70 M HKD.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM